share_log

HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $20 Price Target

Benzinga ·  Jan 4 10:46

HC Wainwright & Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Buy and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment